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Abstract Recently, a draft of the report of the National
Commission on Digestive Diseases was made available
to the public. The Commission was given the task
of assessing the current state of science in digestive
diseases research, and developing a 10-year plan for
digestive diseases research consistent with National
Institutes of Health (NIH)s mission of improving the
health of the nation through research. Twelve topic-
specific areas were selected for organizing the content of
the long-range research plan. One chapter was devoted
to Research on the Basic Biology of the Digestive System
covering major biological pathways which regulate the
physiology and biochemistry of the gastrointestinal
tract. The author wrote about the areas related to neu-
rogastroenterology, endocrinology and satiety. In this
communication, recent advances in these areas are
reviewed and major recommendations for future
research endeavours are highlighted. Collectively,
the recommendations will provide scientific direction
for the NIH and all parties engaged in digestive disease
research as they address opportunities in digestive
diseases research over the next decade.
Keywords brain - gut axis, ENS, motility, NIH research
funding.
GENESIS OF THE NATIONAL
COMMISSION ON DIGESTIVE DISEASE
AND ITS LONG RANGE RESEARCH PLAN
FOR DIGESTIVE DISEASES
Decades of research in digestive disease have contrib-
uted to a significant reduction in the individual and
national burden of many of these diseases. Despite
these successes, the public cost of digestive diseases
in the USA remains significant, and the sheer volume
and scope of these illnesses highlight the crucial need
for attention to these disorders through vigorous
research efforts. In response to congressional report
language accompanying the FY 2005 appropriation
bills in the House and Senate for the Departments of
Labor, Health and Human Services and Education and
related agencies, on 26 July 2005, Elias A. Zerhouni,
M.D., Director of the National Institute of Health,
chartered the National Commission on Digestive
Diseases. The Commission was given the task of
assessing the state of the science in digestive diseases
research and developing a 10-year plan for digestive
disease research consistent with the National Insti-
tutes of Health (NIH) mission of improving the health
of the nation through research. The Commission
comprised 16 members who included academic
researchers, medical professionals and patient advo-
cates, who were appointed by the NIH Director after a
public nomination process. Working groups composed
of experts in diverse areas of digestive diseases
research were formed to assist the Commission to
identify major scientific advances and formulate high-
priority research goals. Approximately six to 10
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members were chosen for each group based on
expertise and knowledge of current research related
to the working group topic. Twelve topic specific
areas were selected for organizing content of the long-
range research plan. One chapter was devoted to
Research on the Basic Biology of the Digestive
System covering major biological pathways, which
regulate development, growth, digestion and meta-
bolism, nutrient and fluid absorption and secretion,
neurophysiology, endocrinology and satiety, microbio-
logy and the microbiome and mucosal immunology.
A draft of the Commissions report was recently made
available to the public. Collectively, the Commis-
sions recommendations will provide scientific direc-
tion for the NIH and all parties engaged in digestive
disease research as they address opportunities in
digestive diseases research over the next decade. The
author wrote about the areas related to neurogast-
roenterology, endocrinology and satiety. In this com-
munication, recent advances in the field are reviewed
and major recommendations for future research
endeavour are highlighted.
LONG-RANGE RESEARCH GOALS AND
RECOMMENDATIONS FOR FUTURE
RESEARCH
The Commission identified a number of long-range
research goals and recommended them as high priority
for future research. These are highlighted with com-
ments from the authors as follows:
(A) Define the basic cellular and molecular
mechanisms responsible for neural activation,
integration and regulation in the enteric nervous
system
The enteric nervous system (ENS) regulates motor
patterns in the gastrointestinal (GI) tract. This division
of the autonomic nervous system has been mapped
extensively in a few animal models, but important
mechanistic questions remain about the organization
and function of enteric neurons and glial cells. Addi-
tional studies characterizing neural reflexes, neural
plasticity, growth and development, and stem cell
biology are needed to allow therapeutic control of
enteric neural function.
A1. Objectives
• Understand the ionic and cellular regulatory
mechanisms responsible for enteric nerve cell activa-
tion, synaptic transmission, integration and motor
pattern development.
A1. Comments Remarkable progress has been made in
the mapping of the ENS and how it is organized to
achieve its role.1 Much is now known about the
properties of individual neurons and how regional
specialization occurs permitting differential function-
ing of the different regions of the GI tract.2 However,
there is much to be learned about the ionic and cellular
regulatory mechanisms responsible for enteric neuron
activation, synaptic transmission, integration and
motor pattern development. Two groups of enteric
neurons deserve special attentions: the intrinsic pri-
mary afferent neurons (IPANS) and the interneurons.
Because IPANs are the initiating neurons for enteric
reflexes that control motility, blood flow and trans-
epithelial movement of fluid in the gut, they are stra-
tegically placed to influence the intensity of the
reflexes. Altered properties of IPANs could conceivably
be involved in the development of intestinal hyper-
sensitivity and altered motility in irritable bowel syn-
drome (IBS).3–5 Compounds that change the
excitability of either the soma or the processes of
IPANs or modify their response to neurotransmitters
or inflammatory mediators may have therapeutic
potential. Interesting targets include sites of sensory
transduction (P2X6 and 5HT3
7) receptors and stretch-
activated ion channels,8,9 ion channels which appear to
be specific to IPANs (IK channels10), TTX-R Ina, NK3
receptors11 and receptors for inflammatory mediators
such as cytokines.12–14
Interneurons mediate motility reflexes and are the
sites of integration. It is important to identify the
molecular and electrophysiological characteristics of
these neurons and learn how they process information
and coordinate sensory and motor reflexes. This is the
first step towards identifying the distinct neural
circuits involved in mediating different motility pat-
terns. By defining the principle receptors, neurotrans-
mitters and synaptic connections for each circuit we
may be able to identify the switch responsible
to change one motility pattern to another. This
kind of information may have important therapeutic
implications.
A2. Objectives
• Characterize the molecular phenotypes of the
different classes of enteric neurons (i.e. sensory, inter-
neurons and motor neurons). Develop unique biomar-
kers to allow evaluation of the state of specific classes
of enteric neurons during the development of GI motor
disorders.
A2. Comments All enteric neurons can be placed in
four functional classes based on their shapes, neuro-
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chemistries, function and cell physiological proper-
ties.1 These are IPANs, interneurons, motor neurons
and intestinofugal neurons. These properties provide
the different classes of enteric neurons with a neuro-
chemical signature. These signature molecules include
the primary transmitters of the neurons, the synthe-
sizing enzymes for the transmitters, molecules that
have transmitter or hormonal roles at other sites in the
body, but are not necessarily transmitters of the enteric
neurons that harbour them, and other markers such as
calcium binding proteins. Thus, a chemical code can be
found that defines enteric neurons and distinguishes
neurons from each functional type. It is conceivable
that this information may allow the scientists to
develop unique biomarkers to identify the class of
neurons which are malfunctioning during the devel-
opment of GI motor disorders.
A3. Objectives
• Determine how enteric neurons function as a
network to generate motor patterns, respond to lumi-
nal contents, produce stereotypical gut reflexes, gen-
erate sensory signals, and adapt to the conditions like
inflammation or stress.
A3. Comments With better understanding of the
roles of the various components of the ENS, we can
begin to identify the distinct neural circuits involved
in mediating different motility patterns. It is impor-
tant to define the principle receptors, neurotrans-
mitters and synaptic connections for each circuit and
identify the switch responsible to change one
motility pattern to another. We need to examine how
mechanical stimulation, metabolic stress and
inflammation can alter these circuits. This type of
information may be important to define the patho-
physiology of IBS and various motility disorders. For
reasons mentioned in A1, special emphasis should be
placed on the IPANs and the interneurons. We need
to characterize fully the plasticity of the channels,
receptors and intracellular control systems of these
neurons in response to inflammation, metabolic
stress and changes in luminal bacteria flora. New
technologies must be developed to visualize the state
of activity of these neurons in live tissues and organs
as they may help us to understand their role in
initiating specific motility patterns.
A4. Objectives
• Understand the development of the ENS and how
adult neural stem cells might facilitate the repair of a
defective ENS resulting from developmental defects or
pathophysiological damage.
A4. Comments Until recently, the postnatal peri-
pheral nervous system was thought to lack stem cells.
A technological breakthrough occurred in 2002. Using
flow cytometry, the Morrison laboratory was able to
identify prospectively and isolate the neural crest stem
cells (NCSCs) that are capable of forming multilineage
colonies in culture.15,16 These investigators showed
that NCSCs persist in the adult gut and undergo
changes in self renewal. These exciting new findings
open up a new possibility for regeneration after injury
or disease. Currently, much remains to be learned
about how the various signals interact to yield a nor-
mal ENS. We should continue to search for clue as we
begin to identify the developmental defects resulting in
neuronal loss such as in Hirschsprungs disease and
hypertrophic pyloric stenosis. We need to identify the
molecules and pathways that promote proliferation
and differentiation of enteric neurons and/or guide the
growth of enteric axons to their target.
A5. Objectives
• Understand the role of glial cells in maintaining
the structure and integrity of enteric ganglia and in
regulating the functions and health of enteric neurons.
A5. Comments The enteric neurons and nerve fibre
tracts are supported by numerous glial cells. In the
central nervous system (CNS), glial cells have an
important role in synaptic transmission, plasticity and
immunoprotection. Glial-derived neurotrophins and
neurotrophic factors such as glial-derived neurotrophic
factor (GDNF) have strong effects on neurite outgrowth
and differentiation and are able to protect neurons from
apoptosis under various inflammatory conditions. It is
likely that glial cells may play similar roles in the ENS.
This needs to be thoroughly investigated. It was
reported that GDNF availability determines enteric
neuron numbers by controlling ENS precursor prolif-
eration.17 GDNF)/) mice have hypoganglionosis in the
stomach and aganglionosis of the small bowel and
colon.18,19 It is conceivable that some of the motility
disorders secondary to degenerative loss of enteric
neurons may be due to structural and/or functional
abnormality of the glial cells. Glial cells also play the
important roles in the maintenance of gut mucosal
integrity.20,21 In human Crohns disease and experi-
mental colitis in rats, the GDNF is upregulated.22 This
neurotrophic factor has strong anti-apoptotic effects on
colonic epithelial cells which may be responsible for
its protective action on the epithelial lining during
mucosal inflammation.22 The mechanisms responsible
for upregulation of the GDNF in inflammatory bowel
conditions should be examined and its cellular actions
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to promote epithelial restitution should be investi-
gated. Alteration of this novel gut neuroepithelial
cross-talk may contribute to a more serve course of
inflammatory bowel disease (IBD).
A6. Objectives
• Understand how inflammatory cells and media-
tors influence neural activation and integration.
A6. Comments Inflammation has widespread effects
on neural activation and integration. The excitability
and synaptic transmission of both the AH- and S-type
submucosal neurons are increased in experimental
colitis in guinea pig.23 The molecular mechanism
responsible for the activation of the intrinsic sensory
neurons during inflammation is not known and may
involve plasticity of receptors, ion channels and intra-
cellular signalling molecules. This is an important area
for research as inflammation may alter sensory per-
ception and activate neural reflex pathways resulting
in abnormal motility. Inflammation seems to have a
differential effect on motor neurons in the GI tract, as
the packaging, storage, and release of neurotransmit-
ters from the motor neurons and sympathetic nerve
endings in the myenteric plexes are impaired.24,25 This
is mediated by inteleukin-1b.26 Impaired function of
the motor neurons in the ENS may result in abnormal
lower oesophageal sphincter (LOS) function and GI
dysmotility. Enteric neurons are not just bystanders
during inflammation; they may actively participate in
the inflammatory response. Cytokines enhance the
release of substance P from sensory neurons and sub-
stance P in turn activates immune cells and modulates
the inflammatory response. Furthermore, the bioavail-
ability of substance P is increased in the inflamed gut
because of the suppression of the tissue level of neural
endopeptidase.27 Thus the multiple levels of cross-talk
between enteric neurons and immune cells may set up a
vicious cycle perpetuating the pathogenesis of chronic
pain. It is conceivable that a greater understanding of the
mechanisms responsible for neuroplasticity in enteric
neurons during inflammation may reveal new and
effective approaches to treatment.
(B) Understand the structure, function and
regulatory mechanisms responsible for motility
in the GI tract
The ENS exerts control over smooth muscle cells to
develop patterns of contractile responses, such as
peristalsis, segmentation, tonic contraction, retroperi-
stalsis and others. ENS control is superimposed upon
spontaneous activity of the musculature (so-called
myogenic activity of smooth muscle tissues) and
contributions from a variety of additional regulatory
systems. A more complete understanding is needed of
the interactions of the ENS with smooth muscle cells
and the mechanisms responsible for regulation of
contractile behaviour to develop the targeted therapies
to improve motor function.
B1. Objectives
• Understand the molecular signalling pathways
responsible for generation of tonic and phasic contrac-
tions in GI muscles and how these pathways are
altered in pathophysiological conditions.
B1. Comments Gastrointestinal smooth muscle
exhibits variable tone, on which are superimposed
rhythmic contractions driven by electrical slow waves.
The physical characteristics of these two types of
contractions and their spatiotemporal patterns, func-
tion and regulatory mechanisms are markedly different
from each other. The slow waves initiated from the
interstitial cells of Cajal (ICC) are mainly responsible
for the initiation of phasic contractions of the smooth
muscle. Ca2+ influx during the depolarization phase of
each slow wave triggers a transient contraction. Phos-
phorylation of the 20-kDa regulatory myosin light
chain (MLC20) is a prerequisite of smooth muscle
contraction. MLC20 phosphorylation during the initial
transient contraction induced by an agonist is medi-
ated by Ca2+/calmodulin dependent MLCK, whereas
MLC20 phosphorylation during the subsequent sus-
tained contraction is mediated by Ca2+-dependent
MLCK and inhibition of MLCP. Multiple signal
transduction pathways and molecules are involved in
the mediation of muscle contraction depending on the
regions of the GI tract and the types of contractions.
Many of these signalling molecules may be affected by
pathological conditions such as inflammation. For
example IL-1b released during inflammation has been
shown to enhance the expression of RGS428 which in
turn accelerates the deactivation of Gaq, leading to
a decrease in phosphoinositide hydrolysis and IP3-
dependent Ca2+ release and the inhibition of initial
contraction and MLC20 phosphorylation.
29 Similarly,
ageing and metabolic disorders such as diabetes can
also alter the expression of key signalling molecules
which regulate muscle contraction. Studies of this
kind may help to identify therapeutic targets for pre-
vention and/or intervention.
B2. Objectives
• Clearly define the role and mechanisms of electro-
mechanical and pharmaco-mechanical coupling in
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generating tone and phasic contractions in GI muscles
and the effects of sex hormones, inflammatory factors
and ageing on these mechanisms.
B2. Comments The ratios of the activities of MLCK
and MLCP determine the net phosphorylation of
MLC20 and this in turn regulate muscle contraction.
The activities of MLCK and MLCP are regulated by
electromechanical and pharmacomechanical cou-
plings. Electromechanical coupling is caused by an
increase in cytosolic free Ca2+ by membrane depolar-
ization and influx through membrane calcium chan-
nels. Abnormalities in slow-wave generation or
propagation or smooth muscle Ca2+ channels may lead
to defective electromechanical coupling. The pharma-
mechanical coupling is caused by the activation of cell
signalling pathways by the binding of ligands to their
membrane receptors, followed by the activation of
kinases that modulate the activity of MLCP or MLCK.
Pharmacomechanical coupling increases [Ca2+]i by the
opening of receptor-operated Ca2+ channels through
non-selective cationic channels, and by release of Ca2+
from the intracellular stores to enhance the phos-
phorylation of MLC20 by MLCK. Different contribu-
tion of electromechanical and pharmacomechanical
couplings in response to an agonists will determine the
type of muscle contraction. These are important
mechanisms for determining the contractile perfor-
mance of smooth muscle cells and they can be affected
by sex hormones, inflammatory factors and ageing.
This is an important area for future research.
B3. Objectives
• Determine the molecular basis for electrical
coupling between GI smooth muscle cells and
between smooth muscle cells and ICC and the
consequences of a breakdown in electrical coupling
on contractile behaviour.
B3. Comments The relationships between electrical
events in ICC and in smooth muscle cells have been
extensively investigated. The ICC form gap junctions
with each other and with smooth muscle cells; these
junctions provide structural basis for electrical cou-
pling between these cells. Slow-wave activity is gen-
erated and actively propagated within the ICC
networks, and slow waves passively spread to neigh-
bouring smooth muscle cells.30 Thus, the loss of slow
waves due to damage of ICC in any parts of the GI tract
might adversely affect its motor performance. Pace-
maker ICC possess distinct channels responsible for
initiation of slow waves and their propagation to
electrically coupled smooth muscle cells. The mecha-
nism appears to involve a localized release in [Ca2+]i
that causes the opening of non-selective cationic
channels in ICC.31 The precise trigger for Ca2+ release
via IP3 receptors in the absence of agonists is unknown.
This is an important area for further investigation as
the regulation of the open probability of IP3 receptor in
ICC is central to the coordination of pacemaker
activity. Furthermore, little is known about voltage-
dependent regulation of IP3 production or another
second messenger that increases the sensitivity of PLC
or other pathways in the ICC. In addition, the molec-
ular entity responsible for the dihydropyridine-resis-
tant channels in ICC has not yet been identified. This
type of information will shed light on the mechanisms
responsible for the generation and propagation of slow
waves in the ICC. Abnormalities in these regulatory
pathways may conceivably lead to motility disorders.
B4. Objectives
• Determine the mechanisms and the role of
calcium sensitization in response to neurotransmit-
ters, hormones and paracrine substances in GI con-
tractile behaviour and whether this mechanism is
altered by inflammation, sex hormones, or ageing.
B4. Comments Ca2+ channels and Ca2+-activated K+
channels are the electrical apparatus that sustains
rhythmicity in smooth muscle. The Ca2+ sensitivity of
K+ channels links their activity to that of Ca2+ chan-
nels and creates the dynamic framework for rhythmic
electrical activity. Excitatory neurotransmitters or
hormones may increase intracellular Ca2+ by inducing
Ca2+ influx and mobilizing intracellular Ca2+ store
resulting in contraction. On the other hand, inhibitory
neurotransmitters act through protein kinase A or
protein kinase G to decrease [Ca2+]i. They do so by
inhibiting Ca2+ release and enhancing sequestration of
Ca2+ in intracellular store, mechanisms that are well
suited to the relaxation of tonic contraction, or by
hyperpolarizing the plasma membrane during slow-
wave activity and reducing Ca2+ influx, a mechanism
well suited to the relaxation of phasic contraction. The
hyperpolarization determines the profile or occurrence
of phasic contractions. It is important to determine the
molecular mechanisms responsible for calcium sensi-
tization as this process can be affected by disease
conditions such as inflammation. Inflammation sup-
presses the Ca2+ current through L-type Ca2+ channels
(Cav 1.2).32 This is mediated by the suppression of the
pore forming aIC subunit of Cav 1.2 channels.32
Molecular studies of this kind are important to
understand how excitation–contraction coupling may
be altered in disease process.
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B5. Objectives
• Determine the basis for spontaneous electrical
activity in smooth muscle cells and tissues and the
mechanisms for propagation of electrical activity in
the generation of motor behaviour of GI organs.
B5. Comments The smooth muscle cell response to
electrical inputs from ICC underlies the motility pat-
terns in GI organs. Slow waves produce a cycle of
depolarization and repolarization that conducts to
smooth muscle cells and changes the open probabili-
ties of the many voltage-dependent ion channels
expressed by smooth muscle cells. Voltage-dependent
ion channels form the backbone of the smooth muscle
response to electrical rhythmicity, but metabotrophic
and Ca2+-dependent ion channels also contribute to the
integrated responses of these cells. Responses are fur-
ther tuned to create the observed motility patterns by
paracrine, hormonal and neural inputs to the smooth
muscle/ICC syncytium. Many of the stereotypical
motility responses of these cells also depend on mod-
ulations of ion channels. Further studies should
emphasize on characterizing the variety and complex-
ity of ion channel expression in GI smooth muscle and
how these elements can be affected by inflammation,
sex hormone or ageing.
B6. Objectives
• Understand stretch-dependent mechanisms that
regulate the excitability of GI smooth muscles and
contribute to patterns such as receptive relaxation,
peristalsis and gut stasis.
B6. Comments Recent studies indicate that ICC
mediate mechanosensitive response in the GI tract.33
This may be achieved by physical transfer of mechan-
ical information at specialized junctions known as seg
and socket junctions.33 Alternatively, the mechanical
force may be transmitted through the production of
prostaglandins.33 Slow waves conduct via low-resis-
tance junctions to smooth muscle cells and decay as a
function of distance from the ICC network. The rate of
decay is dependent on the cable properties of the
smooth muscle syncytium. These are modulated via
the plethora of ionic conductances expressed by
smooth muscle cells. The molecular mechanism reg-
ulating these conductances is an important area of
investigation as they tune the smooth muscle
response. Oscillation of membrane potential through
the slow-wave cycle results in periods of high and low
open probability for Ca2+ channels, and this organizes
the contractile pattern into a series of phasic contrac-
tions contributing to motility patterns such as
peristalsis and segmentation. The force and pattern of
phasic contractions depend on coordination from the
ENS. Neural inputs set the excitability of the smooth
muscle cells by regulating resting membrane potential
or by altering the responses of voltage-dependent
channels to slow-wave depolarizations. Superimposed
on neural regulation are multiple layers of additional
regulation caused by circulating hormones and
paracrine substances. Thus, the final outputs of the
smooth muscle contractions and GI motility are a
highly complex, integrated response involving
multiple cell types and multiple regulatory levels.
Abnormality in any level of regulation may result in
impaired motility. Investigation in this area is likely to
shed new light on the pathogenesis of various motility
disorders.
B7. Objectives
• Determine the effects of inflammatory mediators
on the structure, function and phenotype of GI smooth
muscle cells and ICC.
B7. Comments Inflammation has widespread effects
on the structure and function of smooth muscle cells
and ICC. Through the release of cytokines and other
inflammatory agents, inflammation may have differ-
ential effects on the expression of receptors, G pro-
teins, PKCs or ion channels. The genomic effects on
those key signalling molecules may result in altered
excitation–contraction coupling and muscle contrac-
tile pattern. Inflammation also significantly affects the
structure and function of ICC. The density of ICC is
reduced in the inflamed gut and their processes are
damaged.34 At the same time, it reduces the amplitude
and duration of slow wave. This directly contributes to
a smaller increase in [Ca2+]i and reduction phasic
contractions. The smooth muscle cells are not only
targets of inflammatory mediators but also secrete
inflammatory mediators. For example, acid can acti-
vate vanilloid receptors (TRPV1) present on the squa-
mous epithelial cells that release platelet activating
factor.35 This may increase reactive oxygen species
generation in smooth muscle cells and in turn impair
the LOS tonic contraction. Catalase treatment restores
the weak tonic contraction of circular muscle from a
human donor with erosive oesophagitis. The expres-
sion and secretion of inflammatory mediators by
colonic smooth muscle cells may also be the basis of
persistence of motility dysfunction in patients
with IBD in remission and in patients with postin-
fectious IBS. Hence, research in myoneuroimmune
interaction has important clinical and therapeutic
implications.
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(C) Develop research tools to investigate the
structure and functional organization of the ENS
The multiple constituents of the ENS are characterized
by a dynamic cross-talk between the enteric neurons,
glial cells, ICC, smooth muscle cells and enteroendo-
crine cells. Hence, functional and structural studies
need to be performed with tools that allow dynamic
visualization of the activity of the relevant cells in situ.
Characterization of receptors, channels and signal
transduction systems unique to different cell types
and how they interact with luminal events are critical
to understanding how information is processed in the
coordination of motility, secretion and absorption.
C1. Objectives
• Investigate molecular and electrophysiological
characteristics of various ENS cellular components,
which may be targets for new developments to treat
motility disorders.
C1. Comments The structural and functional organi-
zation of ENS continues to evolve. We need to more
fully characterize the enteric neural networks; under-
stand the cross-talk between the enteric neurons, glial
cells, ICC, smooth muscle cells and enteroendocrine
cells; and define the signal processing within the ENS
in response to nutrient, mechanical stimulation,
inflammation, metabolic stress and changes in bacte-
rial flora. We must investigate the molecular and
electrophysiological characteristics of the various cel-
lular components of the ENS. This includes identifi-
cation of receptors, channels and signal transduction
systems unique to different cell types in the ENS as
they may be targets for new drug developments to treat
motility disorders.
C2. Objectives
• Develop tools to visualize the state of activity of
relevant cells in live tissues, organs and systems.
C2. Comments The multiple constituents of the ENS
can have profound effects on its functioning. In addi-
tion to the nerves and smooth muscle cells, the normal
functioning of the system requires participation of the
ICC, glial cells and enteroendocrine cells. For example,
research on the ICC has dramatically altered the way
we look at regulation of smooth muscle. Interstitial
cells of Cajal pace GI muscle by initiating slow waves
in both muscle layers and appear to be the preferred
sites for reception of neurotransmitters, especially for
acetylcholine and nitric oxide.2 Technically, we must
develop the tools to visualize state of activity of rele-
vant cells (ICC, enteric neurons, muscle cells and
neuroendocrine cells) in a live context of tissue
(in vitro or in vivo), organ and system (in vivo) and
develop quantitative analysis of spatio-temporal
patterns. Ultimately, this may help to elucidate the
roles of various cellular components of the ENS in the
mediation of physiological events such as motility,
sensory transmission, secretion and blood flow. There
is a need to integrate cellular events with whole
system physiology.
C3. Objectives
• Characterize alterations in gut-based 5HT and
corticotropin-releasing factor (CRF) in IBS and motil-
ity disorders, including genetic polymorphisms affect-
ing ligands, receptors, transporters, enzymes and/or
signalling systems.
C3. Comments The recent characterization of the
peripheral serotonin/5HT receptor signalling system in
the ENS represents a major advance in our endeavour
to treat functional bowel disorder.36 Multiple 5HT
receptor subtypes (5HT1, 5HT2, 5HT3 and 5HT4) are
present in the ENS. They mediate neuronal excitability
and synaptic transmission. The differential distribu-
tions of 5HT subtypes36–39 make it possible to use 5HT
antagonists and agonists to treat motility disorder and
IBS. The serotonergic network should be an important
target for new therapeutic approaches.
Given the importance of the peripheral 5HT signal-
ling system in GI motor and sensory disorders, we need
to continue our efforts to characterize the alterations in
the gut-based 5HT signalling system in IBS and
motility disorders. This may include SERT, modula-
tors of SERT expression, and a number of enterochro-
maffin cells and contents. The mechanism responsible
for diminished serotonergic signalling in inflammation
should be examined. Transcripts encoding tryptophan
hydroxylase-1 and SERT can be decreased. Successive
potentiation of 5HT and/or desensitization of its
receptor could account for the symptoms observed in
diarrhoea-predominant and constipation-predominant
IBS respectively. This possibility should be investi-
gated. Genetic polymorphisms affecting 5HT synthe-
sis, receptors, transporters and/or signalling systems
may contribute to the development of IBS. This is an
important area of future investigation.
The CRF signalling pathway coordinates endocrine,
behavioural and immune responses to stress.40 The
Activation of CRF receptor 1 and 2 produces differen-
tial effects on gastric and colonic motility.41–44 Clinical
studies show that stimulation of CRF1 pathways
produces the key symptoms of IBS diarrhoea-predom-
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inant patients.45 These symptoms are alleviated by
CRF1 receptor antagonists supporting the involvement
of the CRF1 system at the central and peripheral sites
in the pathogenesis of IBS triggered by stress.45 The
CRF1 receptor antagonist that is directed at normaliz-
ing a sensitized CRF system holds great promise for a
variety of stress-related GI disorders including IBS and
cyclical vomiting syndrome.46 Further efforts should
be directed at investigating possible abnormalities of
the CRF signalling pathway in IBS patients and
defining the subtypes of IBS patients whom are most
likely to respond to treatment with CRF1 receptor
antagonist.
C4. Objectives
• Identify molecules and pathways that promote
proliferation and differentiation of enteric neurons
and/or molecules responsible for directing enteric
axons to their targets. Define the molecular basis for
chemo- and mechano-receptors in the gut to sense
ingested nutrient environment and gain better under-
standing about interactions between nutrient and
microbe-sensing mechanisms in the gut.
C4. Comments Research to elucidate the events in
early ontogeny will continue to provide important
clues on the mechanism underlying ENS formation.
These studies revealed an ever increasing range of
molecules essential for the normal development of the
ENS. The RET/GFRa1/GDNF signalling pathway plays
a number of key roles during ENS development,
including the promotion of survival and proliferation of
enteric precursors within the gut and their subsequent
differentiation into enteric neurons.47–50 In addition
GDNF is also a potent chemoattractant for neural crest
cell-derived enteric precursor cells.51 Perhaps the most
novel aspect of RET biology is that it induces positive
survival signals in the presence of its ligand GDNF,
and negative cell death signals in the absence of
GDNF.52–53 This may provide an alternate mechanism
for the pathogenesis of Hirschsprungs disease and
other motility disorders due to degeneration of the
ENS. The EDNRB/EDN 3 system provides another
critical signalling pathway necessary for ENS
development. Its activation enables colonization of the
distal hindgut.54 The EDNRB/EDN 3 signalling system
is also important in the maintenance of the neural
crest cells in a multipotential undifferentiated
progenitor-like state.55 This type of studies is impor-
tant as they may shed light on how adult neural stem
cells might facilitate repair of a defective ENS resulting
from developmental defects or pathophysiological
damage.
On a separate subject, there is increased understand-
ing of the biophysical principles of sensory function in
the GI tract. This has important pathophysiological and
therapeutic importance in a number of motility condi-
tions including visceral hypersensitivity and IBS. Infor-
mation on contractile state of the musculature and
distension of the gut wall is coded by mechanoreceptors
which include both low and high threshold mechano-
receptors. The electrophysiological properties of these
receptors may be altered by stress or inflammatory
conditions. Furthermore, there is a third group of
mechanoreceptors known as silent nociceptors which
can be sensitized by inflammatory mediators resulting
in spontaneous firing and responses to normally innoc-
uous mechanical distension. The molecular mecha-
nism responsible for the plasticity of these receptors is
an important area for future research. Sensory trans-
duction of chemical information about luminal nutri-
ent concentrations in the small bowel involves
paracrine signalling from enteroendocrine cells to
spinal and vagal afferent terminals in the gut wall. The
Activation of enteroendocrine cells can be accom-
plished by mechanisms resembling oral taste sensation.
Several enteroendocrine cell types throughout the gut
express T1R 2/3 sweet taste receptors, T2R-family bitter
receptors and/or the taste-specific G protein Gagustducin
and these cells are activated by tastant molecules.56–60
This line of research may be exploited for new drug
development. For example, intestinal L cells, which
secrete GLP1, oxyntomodulin and peptide YY (PYY),
express a pathway for nutrient sensing and signal
transduction previously believed to be limited to taste-
bud cells.60 Because the details of sweet taste receptor
activation are understood at the atomic level, one can
imagine rational design of non-caloric artificial sweet-
eners optimized for the combination of palatable taste
and potent L-cell activation. These might supplement
treatment of obesity and diabetes.61
(D) Characterize the neuromuscular phenotypes
of human GI tissues
Much has been learned in recent decades about the
organization of the ENS and cellular mechanisms
involved in generating normal gut motility patterns.
Most information has come from studies of laboratory
animals. It is important to translate this information
into studies of human GI muscles to determine the
neuromuscular phenotypes driving normal human GI
motility. Although access to human samples is
limited, surgery for GI conditions like cancer or
obesity presents an opportunity for studying human
physiology.
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D1. Objectives
• Understand the excitability and contractility
mechanisms in human GI muscles. Translate
knowledge obtained from animal models to human
physiology.
D1. Comments The physiology of the ENS and the
organization of the control circuits have mostly been
studied in the guinea pig. Although pharmacological
investigations of neurotransmission and immunohis-
tochemical studies innervation patterns suggest that
the enteric neurons in humans are similar to those of
other mammals, detailed information about functional
characteristics of these neurons in humans remain
largely unknown. This is especially true about channel
properties, signal pathways, and electrophysiology of
these neurons as they require fresh human tissues for
investigation and this is not readily available. Animal
models continue to be useful to provide important
information on the organization of the ENS but there
are differences between species such as the arrange-
ment of ganglia and the chemical coding of enteric
neurons. This is critical information to obtain before
we can translate knowledge obtained in animal models
to human physiology.
D2. Objectives
• Understand the structure and function of the
human ENS. Determine which animal models best
simulate the integration and cellular phenotypes of
human enteric neurons.
D2. Comments Essentially, all functional types of
enteric neurons have been characterized by their
shapes, neurochemistries and cell physiological prop-
erties in the guinea pig and more recently in their
orthologs in human and several other species. These
neurons can be placed in four functional classes,
IPANs, interneurons, motor neurons and intestinofu-
gal neurons. Pharmacological investigations of neu-
rotransmission and immunohistochemical studies
indicate that muscle motor neurons and secretomotor
neurons in humans are similar to those in other
mammals, and that human equivalents of IPANs have
been identified.1 The interneurons are more difficult
to study but current information suggests that they
are similar to those of other species. As documented
in A2, the shapes, neurochemistries, function and cell
physiology properties provide the different classes of
enteric neurons with a neurochemical signature. This
information conceivably may allow us to develop
unique biomarkers to identify the class of neurons
which are malfunctioning in GI motility disorders.
Hence, an important task will be to determine the
chemical identifiers of each class of the functionally
defined neurons in the human ENS. This will
be important for future investigations of enteric
neuropathology.
D3. Objectives
• Characterize motor innervation of the human
muscularis and identify the major neurotransmitters,
the cells that are innervated by motor neurons, and
the mechanisms of postjunctional neural responses.
D3. Comments The motor neurons of the ENS in
humans appear to be analogous to those in other mam-
mals, the excitatory motor neurons being Dogiel type I
cholinergic neurons with tachykinin immunoreactivity
and the inhibitory motor neurons being anally project-
ing Dogiel type I neurons with nitric oxide synthase and
vasoactive intestinal polypeptide (VIP) immunoreac-
tivity. These deductions are supported by pharmaco-
logical investigations of enteric reflexes in human
intestine.62 Retrograde labelling and immunocyto-
chemistry studies suggest that VIP-containing secreto-
motor neurons occur in human intestine. Most of these
neurons also contain acetyl choline as well. In the colon,
VIP and acetylcholine are found in distinct enteric
neurons.63 The functional significance of these regional
differences in the neurontransmitter contents of human
motor neurons requires further investigation. Apart
from supplying smooth muscle and secretory epithe-
lium, motor neurons may also supply blood cells and
innervate entero-endocrine cells. In human, motor
neurons are mono-axonal, and almost all have S-type
electrophysiological properties. Studies on the struc-
tural and functional characteristics of motor neurons in
human are of great clinical importance as many of the
GI dysmotility disorders may be traced to malfunction
of the motor neurons within the ENS.
D4. Objectives
• Define the receptors and signalling pathways that
are involved in neural, hormonal and paracrine regu-
lation of human GI muscle function.
D4. Comments Multiple receptors and signal trans-
duction pathways exist in smooth muscle cells and
ICC. They mediate and condition the response of
smooth muscles to slow-wave depolarizations and
humoral substances like hormones, paracrine sub-
stance and inflammatory agents. The sites of action of
some of these bioactive substances may also be at ICC,
but the importance of ICC as targets for these agents in
human is poorly understood. Several motility disorders
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have been associated with loss of ICC, thus investiga-
tion of these cells in humans may shed light on the
pathogenesis of some of the motility disorders. Fur-
thermore, alteration in receptor numbers or affinity or
signal transduction pathways may occur in smooth
muscle cells or ICC in response to inflammation or
metabolic stress. This is an important area of investi-
gation in human motility disorders.
D5. Objectives
• Develop methods of organ or cell culture that
preserve the phenotypes of human muscle cell com-
ponents. Determine methods to culture smooth mus-
cle cells, ICC, enteric neurons and other cellular
components without dramatic changes in the native
phenotype.
D5. Comments As access to human samples is always
going to be limited, primary cells derived from humans
with defined attribute would enable in vitro studies to
characterize the signalling pathways of various cell
types found in the ENS. Important cell lines to be
defined and established include NCSCs, progenitors of
ICC, glial cells and specific native neurons and ente-
roendocrine cells. To do so, it will be important to
develop better cell specific markers. In addition, inno-
vative techniques are required for the long-term
maintenance of cells in culture under circumstances in
which cells do not undergo major change in their
characteristics. Moreover, central facilities to acquire
and maintain these cells for distribution would be
helpful.
(E) Integrate cellular events in ENS with whole
system physiology and translate findings to
pathophysiological conditions
Normal functioning of the GI tract requires different
components of the ENS to operate in unison, empha-
sizing the importance of identifying relationships in an
organismal context. Advances in neurobiology of
brain–gut interaction, together with availability of
new neuroimaging modalities, greatly enhance our
ability to study functional GI disorders and search for
new therapeutic targets. Recognition of the GI tracts
crucial role in satiety signalling and control of energy
homeostasis, body weight and various metabolic sys-
tems provides a new framework to study the disorders
of energy homeostasis. Pathophysiological models
coupled with genomic analysis offer new opportunities
to discover molecular mechanisms responsible for age-
related neuron degeneration and provide avenues to
reconstitute the ENS networks in diseased organs.
E1. Objectives
• Identify distinct brain circuits responsible for
various gut functions and pain perception and char-
acterize the signalling systems and receptors within
these neural circuits using PET ligand imaging in
rodent models and humans with IBS and functional
dyspepsia.
E1. Comments Major advances have been made in our
ability to image the living human brain with various
neuroimaging modalities.64 This has greatly enhanced
our ability to study brain–gut interactions in health
and in disease conditions. Symptom components of IBS
can be dissected and attributed to specific areas of the
brain that mediate cognitive, emotional and motiva-
tional component of the discomfort.64,65 This new
approach to the study of functional GI disorders pro-
vides more insightful information on the pathophysi-
ology of this group of disorders. Efforts to characterize
the signalling systems and receptors in these neural
circuits using PET ligand imaging in rodent models and
humans may provide novel therapeutic targets for
rationale design of new drugs to treat IBS and func-
tional dyspepsia. Furthermore, the ability to study a
neurobiological substrate with imaging modalities
rather than relying on highly variable subjective
symptoms (e.g. Rome criteria) makes it possible to
investigate the role of genetic factors66 and receptor
physiology67 on the pathophysiology of symptoms. We
should have a precise endpoint to evaluate therapeutic
interventions on distinct brain networks involved in
afferent processing and modulation. Meaningful
results from such studies can be obtained from much
smaller samples of subjects compared with epidemio-
logical or traditional pharmacological studies.
E2. Objectives
• Develop contemporary techniques for probing
genetic and proteomic changes that occur with age.
Establish the mechanism that maintains the integrity
of the ENS and its capacity to respond to altered
function or plasticity in adulthood and old age.
E2. Comments Degenerative and developmental loss of
enteric neurons continues to be the main cause of severe
motility disorders. We need to have a better under-
standing of the molecular mechanisms underlying
age-related apoptosis of ENS neurons. Contemporary
techniques for probing genetic and proteomic changes
that occur with age, such as the use of oligonucleotide
microarray and protein chip technologies, will help the
field to evolve from phenomenology to hypothesis-dri-
ven research. It is important to establish the mecha-
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nisms that maintain the integrity of the adult ENS and
its capacity to respond to altered function or plasticity
in adulthood and old age. Studies of neurotrophic and
growth factors and the associated signalling pathways
may provide some clues for this type of investigation.
E3. Objectives
• Investigate the cellular and molecular mecha-
nisms of neural and endocrine bi-directional commu-
nication between the gut and the CNS for regulation of
weight and metabolic function and the associated
neurohumoral events.
E3. Comments Obesity research remains the top pri-
ority for investigators in the United States. The
capacity to adjust food intake in response to changing
energy requirements is essential for survival and good
health. We need to define the diverse blood-borne and
affective neural signals that transmit information
regarding nutrient status and energy stores to the brain
where it is integrated with cognitive, visual, olfactory
and taste cues. Understanding the complexity of this
energy homeostasis system will then allow us to start
to search for mutation of key molecules mediating
these pathways in patients with severe obesity.
Currently, little is known about the site and mech-
anisms by which alterations in blood glucose levels and
other nutrients are sensed. Comprehensive studies
must be performed to investigate the peripheral mech-
anisms of nutrients sensing. The sites are likely to
involve the CNS as well as the vagal afferent fibres that
may mediate gastric motility, satiety and hepatic
glucose uptake and outputs. Abnormality of this path-
way may occur in patients with diabetes and/or obesity.
Further studies are needed to understand the cellular
and molecular mechanisms of neuro and endocrine
bidirectional communication between the GI tract and
CNS to regulate body weight and metabolic function.
Most of the satiation and orexigenic peptides are found
in the GI tract.68 These include ghrelin, GLP1, PYY,
oxyntomodulin and urocortin. Rationale manipulation
of the neuroendocrine pathways regulating apeptide
may be used to treat obesity. For example, bariatric
surgery works primarily by physiological rather than
mechanical mechanisms. A better understanding of
the physiological and molecular mechanisms by which
bariatric surgery improves body weight and metabolic
regulation might shed light on novel mechanisms we
can manipulate to treat obesity.
E4. Objectives
• Develop suitable animal models to mimic diseases
of the ENS.
E4. Comments Progress in the research of functional
bowel disease is partly hampered by lack of suitable
animal models to mimic the disease conditions.
Although animal models of visceral hypersensitivity
are available, they are not ideal as the pathophysiology
may be quite different. We need to establish scientific
criteria to determine the validity of animal models for
IBS and other motility disorders. Furthermore, the
current range of animal models for studying motility
disorders and functional bowel diseases could be
expanded by the development of tools that permit
targeted genetic studies in various animal models
within specific tissues and cell types of the ENS.
Validation of specific promoters and/or minigenes that
drive tissue- or segment-specific gene expression in
mouse and other relevant models is required. Efforts to
strengthen neurogastroenterology research across the
scientific community might include: (i) establishment
of a coordinated system that would allow for the
identification, characterization and distribution of
suitable mouse lines in a defined background, includ-
ing conditional gain and loss of function alleles that
can be induced in a temporally regulated manner and
(ii) develop centralized animal resources to serve as a
repository of useful models to facilitate research on
molecular pathophysiology of disease development.
(F) Translate knowledge of the ENS in digestive
health and disease into diagnostics and therapies
for human disease
Research on the pathophysiology of human motility
disorders needs to be aggressively translated into the
treatment of human diseases. This includes advances
in neuroimaging modalities to study brain–gut inter-
actions, efforts to unravel the complexity of energy
homeostasis systems, an understanding of some of the
key neural circuits in the ENS, and knowledge of
developmental biology and organogenesis, which allow
for manipulation of neural stem cells in the bowel wall
for replacement therapy.
F1. Objectives
• Determine specific gene profiles in tissues that
suffer ICC or neuron loss or in tissues in the process of
losing these elements and develop a molecular test to
detect these pathological changes.
F1. Comments Our understanding of ICC pathology is
still in its infancy, but a picture is beginning to emerge
that many disparate motility disorders result in loss of
ICC. Mechanisms responsible for the demise of ICC
are poorly understood. One approach is to make large-
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scale screenings of genetic changes that occur in tis-
sues undergoing loss of ICC and investigate whether
there are common genetic fingerprints that either
produce or result from loss of ICC. Pathophysiological
models coupled with genomics analyses may offer the
opportunity to discover why the ICC is vulnerable in
apparently disparate motor disorders and how to
recover ICC networks in disease organs. From these
studies, it may be possible to determine specific gene
profiles that occur in tissues that have suffered ICC
loss, or in tissues in the process of losing ICC. This
information may allow scientists to design specialized
tests that reliably evaluate the status of ICC networks
from biopsy material. Development of a molecular test
that could pick up pathological changes more reliably
and at earlier time points may be highly beneficial as
we may be able to halt the degeneration and minimize
damage and loss of function.
F2. Objectives
• Develop neural imaging techniques to correlate
individual circuits identified with symptom produc-
tion in IBS patients and establish correlation with
distinct genotypes through such approaches as
a genome-wide search for polymorphisms and
haplotypes.
F2. Comments Advances in neuroimaging studies of
the CNS should facilitate our efforts to identify distinct
brain circuits responsible for various GI functions and
pain perception. Once this information becomes avail-
able, we should characterize the signalling systems and
receptors within these neural circuits using PET ligand
imaging in rodents and in humans. Ultimately, we
should be able to correlate the individual circuits iden-
tified with symptom production in patients (interme-
diate phenotypes) and establish correlation with
distinct genotypes that include a genome-wide search
for polymorphism and haplotypes. Ultimately, we need
to be able to characterize fully the pathomechanisms
underlying symptom generation in common functional
and motility disorders, including identification of ge-
netic and early environmental influences and natural
course of the disease. This should lead to more effective
prevention and therapeutic intervention.
F3. Objectives
• Develop neuron replacement therapy to guide the
growth of enteric axons to their targets as a therapy for
neural degenerative disease of the ENS.
F3. Comments In addition to the study of in vivo
migrating behaviour of ENS precursor cells and the
characterization of guidance molecules on axonal
growth. Information on local tissue microenviron-
ments (niches) that maintain and regulate stem cells
has begun to emerge.69 Gut NCSCs may lie dormant
and can then be activated following injury. This
appears to occur under tightly controlled niches.
Niches changes may occur with age and contribute to
tissue ageing. Research in this arena may provide new
preventive or therapeutic approaches to degenerative
neuron loss of the ENS. Currently, most of the infor-
mation on the environmental mechanisms that regu-
late stem cell function is obtained from invertebrate
systems where stem cells from a variety of tissues can
be imaged and genetically modified. Technical
advances will be required in the vertebrate systems to
improve imaging of stem cells at a single cell resolu-
tion. This will allow the verification of the true iden-
tity of the cell studied based on the markers it
expresses. It is also important to systematically test
mechanisms that are proposed to regulate stem cell
maintenance using genetics. A better understanding of
the mechanisms that regulate stem cell maintenance
will facilitate development of new strategies to pro-
mote tissue regeneration after injury and to maintain
stem cell activity during ageing.
F4. Objectives
• Characterize the molecular, cellular and behavio-
ural mechanisms that link changes of stored body fat
to adaptive adjustments of feeding behaviours by
defining the diverse blood-borne and affective neural
signals that transmit information regarding nutrient
status and energy stores to the brain where it is
integrated with cognitive, visual, olfactory and taste
cues.
F4. Comments Leptin is produced in white adipose
tissue and circulates in proportions with the adipose
mass, increasing in plasma as animals and humans
become obese and decreasing in times of food depri-
vation. Thus, leptin provides a signal of the availability
of the bodys energy stores. Another adiposity factor
important for the long-term control of energy balance
is insulin which is also secreted in proportion to body
mass. Both leptin and insulin interacts with same
hypothalamic circuits to affect overall energy balance.
Animal and human studies suggest that insensitivity
to leptin and insulin may be responsible for obesity in
some individuals.70–71 The cellular and molecular
mechanisms responsible for this phenomenon await
further investigation. With a better understanding of
the hypothalamic systems involved in feeding control,
we can begin to identify the distinct neural circuits
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responsible for within-meal and across-meal signalling.
There is still much to be learned about how various
satiety peptides, neural signals and micronutrients
interact at the level of the hypothalamus to modulate
food intake and energy homeostasis. At a molecular
level, phosphorylation of AMP-activated protein
kinase (AMPK) in the hypothalamus appears to play a
critical role in regulating feeding behaviour.72 It is
conceivable that AMPK may act as a physiological
energy sensor within the hypothalamus, and that
alterations in AMPK may be a common final readout of
variety of treatments that act within the basal hypo-
thalamus to affect energy balance. This is an important
area for further investigation.
The molecular mechanism linking adiposicity to
overnutrition remains unknown. Recent literature
suggests that gastric inhibitory polypeptide (GIP) is a
key molecule linking overnurtition to obesity. Exces-
sive fat intake induces hypersecretion of GIP, which
increases nutrient update and triglyceride accumula-
tion at the adipose sites. This can readily cause obesity
and hyperinsulinaemia. Hyperinsulinaemia will fur-
ther increase nutrient uptake into adipose sites, com-
pleting a vicious cycle of developing adiposicity.
Further studies should be performed to explore the
possibility of GIP abnormalities in patients with
overnutrition and obesity.
CONCLUDING REMARKS
Advances in the molecular biology sciences and
proteomics represent an unprecedented opportunity
for us to understand key biological pathways pertain-
ing to the neuroendocrine system of the GI tract. The
unravelling of the complex signalling between diverse
cells in the ENS provides a cellular and molecular
basis for understanding many disorders in the ENS. In
the past, the quest for therapeutic targets and lead
molecules has concentrated on neurotransmitters,
hormones and their receptors. However, much more
is now known about ion channels and intracellular
messengers that control excitability of enteric neu-
rons, the effector cells they innervate, and the entero-
endocrine cells that activate enteric primary afferent
neurons. The ion channels and intracellular messen-
gers may provide new and viable targets. The neuro-
biology of brain–gut interactions has become better
characterized, providing the necessary conceptual
framework for developing new treatments of func-
tional GI diseases and motility disorders. There is
renewed and expanded interest in the role of the GI
tract in the regulation of satiety and energy homeo-
stasis. Increased understanding of the mechanism
governing nutrient sensing and peptide secretion by
enteroendocrine cells allows investigators to exploit
these pathways in the development of new agents to
combat obesity and diabetes. A better understanding
of the molecular mechanisms leading to disease and
age-related apoptotic cell death provides hope for
preventive and/or regenerative therapy. Impressive
recent advances in the identification of molecules
that are involved in regulating the differentiation,
maturation and guidance to targets of enteric neurons
may provide the ways to restitute neuropathic defi-
ciencies that lead to disordered GI function. The
Commission identified a set of high priority goals for
which coordinated research efforts would accelerate
progress across the digestive disease research field
including neurogastroenterology. The stage is set to
put that knowledge to advantage in improving the
treatment of patients with GI disorders.
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